Safety and Efficacy of Low‐Dose Venetoclax Plus Voriconazole in Patients With Acute Myeloid Leukemia Unfit for Intensive Chemotherapy
Hematological Oncology · 2025
DOI: 10.1002/hon.70113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, 2025. Verfasst von Xinyao Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Voriconazole, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Research Project of Health Commission of Anhui Province.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Low‐dose venetoclax plus strong CYP3A4 inhibitor voriconazole were commonly used for acute myeloid leukemia (AML) patients who were unfit for intensive chemotherapy in China. However, the efficacy and safety of this schedule have not been well investigated. We analyzed clinical data from 54 patients with a median age of 67 years. Thirty patients received a standard dose of venetoclax plus azacitidine (cohort 1), whereas another 24 patients received low‐dose venetoclax plus voriconazole plus azacitidine (cohort 2). The composite complete remission (complete remission or complete remission with incomplete hematologic recovery; CR/CRi) rate was 76.7% (23/30) in cohort 1 and 87.5% (21/24) in cohort 2 ( p = 0.483). At a median follow‐up of 16 months, the median progression‐free survival was 12 months in cohort 1 and 18 months in cohort 2 ( p = 0.241). The median overall survival was 14 months in cohort 1 and 19 months in cohort 2 ( p = 0.453). Key adverse events included cytopenia and infections. Grade 3 or higher infections occurred in 36.7% of the patients in cohort 1 and 20.8% of those in cohort 2. In conclusion, this study demonstrated the safety and effectiveness of the combination of low‐dose venetoclax and voriconazole in unfit AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
- School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
ORCID-Profile: Zhangbiao Long
Förderung
- National Natural Science Foundation of China
- Research Project of Health Commission of Anhui Province
Zitieren
APA
Liu, X., Meng, D., Li, Y., Ruan, M., Huang, Z., Wu, W., Ge, J., Yang, J., & Long, Z. (2025). Safety and Efficacy of Low‐Dose Venetoclax Plus Voriconazole in Patients With Acute Myeloid Leukemia Unfit for Intensive Chemotherapy. Hematological Oncology. https://doi.org/10.1002/hon.70113
Vancouver
Liu X, Meng D, Li Y, Ruan M, Huang Z, Wu W, et al. Safety and Efficacy of Low‐Dose Venetoclax Plus Voriconazole in Patients With Acute Myeloid Leukemia Unfit for Intensive Chemotherapy. Hematological Oncology. 2025. doi:10.1002/hon.70113
BibTeX
@article{Liu2025,
author = {Liu, Xinyao and Meng, Danchen and Li, Yuxin and Ruan, Min and Huang, Zhenqi and Wu, Wei and Ge, Jian and Yang, Jichun and Long, Zhangbiao},
title = {Safety and Efficacy of Low‐Dose Venetoclax Plus Voriconazole in Patients With Acute Myeloid Leukemia Unfit for Intensive Chemotherapy},
journal = {Hematological Oncology},
year = {2025},
doi = {10.1002/hon.70113}
}
EUVIMED